NCT07798778招募中1 期
To Evaluate the Safety, Tolerability, Radiation Dosimetry, Pharmacokinetics, and Preliminary Antitumor Efficacy of SRT-017 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Affiliated Hospital of Jiangnan University1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2026年7月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Outcome Measure：Percentage of Participants With Confirmed PSA Response (≥50% PSA Decline)
研究概览
简要总结
This is a single-arm, open-label study to evaluate the safety, tolerability and preliminary anti-tumor efficacy of SRT-017 radioligand therapy in patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC). All eligible participants will receive SRT-017 intravenous treatment. The primary objectives are to assess safety and tolerability. Secondary objectives include radiation dosimetry, pharmacokinetics, and preliminary antitumor activity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male participants aged 18 years or older.
- •Histologically or cytologically confirmed prostate adenocarcinoma with metastatic castration-resistant prostate cancer (mCRPC). mCRPC is defined as disease progression under continuous androgen-deprivation therapy (ADT) or after prior bilateral orchiectomy, with serum testosterone maintained at castrate level (<50 ng/dL or <1.7 nmol/L), meeting at least one of the Prostate Cancer Working Group 3 (PCWG3) progression criteria: PSA progression (PSA ≥1 ng/mL, ≥25 % increase compared with PSA nadir with an absolute rise ≥2 ng/mL confirmed by two consecutive measurements at least 1 week apart); or radiographic progression (≥2 new bone metastatic lesions on bone scan, or soft-tissue disease progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)).
- •Disease progression after treatment with at least one novel androgen-axis drug (NAAD), including abiraterone, enzalutamide, apalutamide, or darolutamide.
- •Prior chemotherapy, or participants who are ineligible for chemotherapy or decline chemotherapy.
- •PSMA-positive lesions confirmed by PSMA-PET/CT imaging; PSMA-positive is defined as tumor lesion uptake higher than liver background uptake.
- •At least one measurable lesion by RECIST 1.1 criteria OR at least one bone metastasis lesion by PCWG3 criteria.
- •Eastern Cooperative Oncology Group (ECOG) performance status score ≤
- •Estimated life expectancy of at least 6 months.
- •No transfusion of blood products, hematopoietic growth factors, or albumin within 14 days before baseline laboratory tests, and adequate organ function as follows: hematologic: absolute neutrophil count ≥ 1.5 × 10⁹/L, white blood cell count ≥ 3.0 × 10⁹/L, platelet count ≥ 100 × 10⁹/L, hemoglobin ≥ 9 g/dL; hepatic: albumin ≥ 30 g/L, total bilirubin ≤ 1.5 × upper limit of normal (ULN), alanine aminotransferase (ALT) / aspartate aminotransferase (AST) ≤ 3 × ULN (without liver metastases) or ALT/AST ≤ 5 × ULN (with liver metastases); renal: serum creatinine ≤ 1.5 × ULN; coagulation: international normalized ratio (INR) ≤ 1.5, activated partial thromboplastin time (APTT) ≤ 2 × ULN.
- •Willing to comply with radiation-protection instructions and scheduled study follow-up procedures.
- •Able to understand study procedures and voluntarily provide written informed consent, and willing to comply with all study-related assessments and follow-up requirements.
排除标准
- •Participants unable to tolerate required imaging examinations.
- •Received systemic anti-tumor therapy (chemotherapy, radiotherapy, immunotherapy; endocrine therapy is exempt), investigational medicinal products, or investigational medical devices within 4 weeks prior to first study drug administration.
- •Received prior radiopharmaceutical therapy (such as strontium-89, samarium-153, rhenium-186, rhenium-188, radium-223, lutetium-177) within 6 months before first dose; or received external-beam radiation therapy (EBRT) within 2 months before first dose.
- •Persistent Grade 4 myelosuppression from prior anti-cancer therapy within 2 weeks before screening, or Grade 3 myelosuppression with recovery duration longer than 6 weeks.
- •Plan to receive cytotoxic chemotherapy, anti-tumor immunotherapy, radioligand therapy, or other similar anti-cancer treatments during study participation.
- •Known brain metastases identified at screening.
- •History of other malignant neoplasms within the past 5 years (curative-treated localized tumors such as basal-cell or squamous-cell skin cancer are permitted).
- •Symptomatic or impending spinal cord compression.
- •Prior external-beam radiation therapy covering more than 25 % of bone-marrow-containing skeletal regions.
- •Significant uncontrolled cardiovascular disease at screening: QTcF > 470 ms or known long QT syndrome; myocardial infarction, angina pectoris, or coronary artery bypass graft (CABG) within 6 months before screening and judged unsuitable for study entry by investigator.
- •Uncontrolled bladder-outlet obstruction, urinary incontinence, claustrophobia, or radiophobia at screening.
- •Positive screening serology for hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, or syphilis antibody.
- •Hepatitis B surface antigen (HBsAg) positive with active hepatitis B virus (HBV) replication as assessed by HBV-DNA testing and investigator judgment.
- •Known hypersensitivity to proteins/peptides, drug excipients, or structurally related compounds.
- •Documented history of drug or alcohol abuse or chronic substance dependence within 1 year prior to screening.
- •Unwilling to practice effective contraception during study participation and for 6 months after last study drug administration.
- •Severe active ongoing infection at the time of first planned study drug administration.
- •Any other medical condition which, in the investigator's judgment, may compromise participant safety, interfere with study result interpretation, or confer unacceptable participant risk.
研究组 & 干预措施
SRT-017-001 Radioligand Therapy Group
Experimental
Male patients with metastatic castration-resistant prostate cancer (mCRPC) will receive investigational PSMA-targeted radiopharmaceutical SRT-017-001 by intravenous injection according to the study protocol.
干预措施: SRT-017 (Drug)
结局指标
主要结局
Outcome Measure：Percentage of Participants With Confirmed PSA Response (≥50% PSA Decline)
时间窗: From first study drug administration up to 12 weeks post-treatment
Proportion of participants achieving confirmed ≥50% PSA reduction from baseline according to PCWG3 criteria. Confirmation requires a second PSA measurement at least 4 weeks later sustaining ≥50% decline.
次要结局
未报告次要终点
研究者
Chunjing Yu
Chief Physician, Department of Nuclear Medicine
Affiliated Hospital of Jiangnan University
研究点 (1)
Loading locations...
相似试验
招募中
2 期
SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaNCT07700667Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.120
招募中
2 期
SKB500 Combinations in Patients With Small Cell Lung CancerSmall Cell Lung CancerNCT07296809Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.80
尚未招募
2 期
A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial CarcinomaNCT07636772Akeso132
招募中
2 期
A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast CancerAdvanced Breast CancerNCT07591090Akeso200
尚未招募
1 期
Study of TYK-01054 Capsules in Patients With Advanced Solid TumorsNCT07282873TYK Medicines, Inc219